-+ 0.00%
-+ 0.00%
-+ 0.00%
Immunovant CEO Eric Venker disposes of common shares worth $2.93 million
Share
Listen to the news
Immunovant CEO Eric Venker disposes of common shares worth $2.93 million
  • Immunovant CEO and director Eric Venker increased his direct stake to 257,075 shares following CVAR settlement.
  • 92,187 shares were acquired on Oct. 1, 2026 at $14.46 per share via an exercise transaction.
  • 85,886 shares were disposed of on Oct. 1, 2026 at $33.65 per share.
  • Another 3,506 shares were sold on Oct. 2, 2026 at $34.11 per share to cover tax withholding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764013-26-000110), on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending